A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.

Influenza, Human Clinical Trial

Official title:

A Phase 3, Randomized, Multicenter, Double-blinded Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Influenza Vaccine (CSL QIV) in Comparison With a US Licensed 2014/2015 Trivalent Influenza Vaccine (CSL TIV-1), and a Trivalent Influenza Vaccine Containing the Alternate B Strain (CSL TIV-2), in Adults Aged 18 Years and Above.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02214225
• Other study ID #: CSLCT-QIV-13-01
• Status: Completed
• Phase: Phase 3
• First received: August 10, 2014
• Last updated: February 21, 2016
• Start date: August 2014
• Est. completion date: April 2015

Study information

• Verified date: February 2016
• Source: bioCSL PTY LTD
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This is a study to assess the immune (antibody) response and safety of a bioCSL split virion, inactivated quadrivalent influenza vaccine, in comparison with a US licensed 2014/2015 trivalent influenza vaccine (bioCSL TIV-1), and a trivalent influenza vaccine containing the alternate B strain (bioCSL TIV-2), in healthy adult volunteers aged 18 years and above.

Description:

This multicenter, randomized, double-blinded study was conducted during the 2014-2015 Northern Hemisphere influenza immunization season to evaluate the non-inferior immune response of bioCSL QIV to that of bioCSL TIV-1 and bioCSL TIV-2 along with safety in healthy male and female adults aged ≥ 18 years. Each vaccinated subject had a maximum 25 day on-study period with a six month safety follow-up.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 3484
• Est. completion date: April 2015
• Est. primary completion date: November 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Males or non-pregnant females aged = 18 years at the time of vaccination.

• Females of child-bearing potential (i.e., ovulating, pre-menopausal, not surgically sterile) must be abstinent or be willing to use a medically accepted contraceptive regimen for the duration of the On-study period. Females of child-bearing potential must return a negative urine pregnancy test result prior to vaccination with the vaccine.

Exclusion Criteria:

• Known hypersensitivity to a previous dose of influenza vaccine or allergy to eggs, chicken protein, neomycin, polymyxin, or any components of bioCSL influenza vaccines.

• Vaccination against influenza in the previous 6 months.

• Known history of Guillain-Barré Syndrome or other demyelinating disease.

• Clinical signs of active infection and/or an oral temperature of = 100.4°F (38.0°C).

• A clinically significant medical condition.

• Pregnant or lactating females.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Influenza, Human

Intervention

Biological:
• Quadrivalent Influenza Vaccine (QIV)
One 0.5 mL intramuscular dose into the deltoid muscle
• Trivalent Influenza Vaccine (TIV-1)
One 0.5 mL intramuscular dose into the deltoid muscle.
• Trivalent Influenza Vaccine (TIV-2)
One 0.5 mL intramuscular dose into the deltoid muscle.

Locations

Country	Name	City	State
United States	Site 283	Austin	Texas
United States	Site 316	Bellevue	Nebraska
United States	Site 285	Binghamton	New York
United States	Site 308	Bristol	Tennessee
United States	Site 302	Charlotte	North Carolina
United States	Site 303	Charlottesville	Virginia
United States	Site 282	Forth Worth	Texas
United States	Site 296	Huntsville	Alabama
United States	Site 297	Jacksonville	Florida
United States	Site 311	Jefferson City	Tennessee
United States	Site 304	Knoxville	Tennessee
United States	Site 312	Knoxville	Tennessee
United States	Site 298	Las Vegas	Nevada
United States	Site 286	Los Angeles	California
United States	Site 293	Melbourne	Florida
United States	Site 289	Meridian	Idaho
United States	Site 310	Methuen	Massachusetts
United States	Site 301	Milford	Connecticut
United States	Site 295	Mishawaka	Indiana
United States	Site 307	Mount Pleasant	South Carolina
United States	Site 299	Oklahoma City	Oklahoma
United States	Site 294	Peoria	Illinois
United States	Site 306	Raleigh	North Carolina
United States	Site 313	Rochester	New York
United States	Site 291	Rockville	Maryland
United States	Site 287	Saint Louis	Missouri
United States	Site 300	Salt Lake City	Utah
United States	Site 288	San Angelo	Texas
United States	Site 315	San Diego	California
United States	Site 292	Savannah	Georgia
United States	Site 309	Wilmington	North Carolina
United States	Site 305	Winston-Salem	North Carolina
United States	Site 317	Witchita	Kansas

Sponsors (1)

Lead Sponsor	Collaborator
bioCSL PTY LTD

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Postvaccination Geometric Mean Titer (GMT) (Statistical Analysis: GMT Ratios) in Subjects Aged =18 Years (Per Protocol Population).	Immunogenicity was assessed by measuring HI titers to the four virus strains. Postvaccination GMTs were determined. (GMT dispersion values are based on unadjusted GMT values.) The GMT ratio (defined as the geometric mean of postvaccination (day 21) HI titer for TIV divided by the geometric mean of the postvaccination HI titer for QIV) for each virus strain included in the vaccines was then determined: bioCSL TIV-1 and bioCSL TIV-2 GMTs were pooled for analysis of the A strains.	21 days after vaccination.	No
Primary	The Seroconversion Rate (SCR) (Statistical Analysis: Difference in SCR) in Subjects Aged =18 Years.	SCR (defined as the percentage of subjects with either a prevaccination HI titer < 1:10 and a postvaccination HI titer = 1:40 or a prevaccination HI titer = 1:10 and a 4-fold increase in postvaccination HI titer) was determined for each virus strain included in the vaccines: bioCSL TIV-1 and bioCSL TIV-2 SCRs were pooled for analysis of the A strains. The SCR difference was defined as the SCR percentage for bioCSL Pooled TIV or TIV-1 (B Yamagata) or TIV-2 (B Victoria) minus the SCR percentage for bioCSL QIV.	21 days after vaccination.	No
Secondary	Postvaccination GMT (Statistical Analyses: GMT Ratios) Assessed Separately Within Each Age Group (18 Through 64 Years and = 65 Years of Age) (Per-Protocol Population).	Immunogenicity was assessed by measuring HI titers to the four virus strains. Postvaccination GMTs were determined. (GMT dispersion values are based on unadjusted GMT values.) The GMT ratio (defined as the geometric mean of postvaccination (day 21) HI titer for TIV divided by the geometric mean of the postvaccination HI titer for QIV) for each virus strain included in the vaccines was then determined: bioCSL TIV-1 and bioCSL TIV-2 GMTs were pooled for analysis of the A strains.; Non-inferiority of bioCSL QIV compared to bioCSL TIV-1, and to bioCSL TIV-2 was assessed separately within each age group (18 to < 65 years and = 65 years of age) through assessment of GMT ratios as described for the primary endpoint.	21 days after vaccination.	No
Secondary	The Seroconversion Rate (SCR) (Statistical Analyses: Difference in SCR) for Each Virus Strain, Assessed Separately Within Each Age Group (18 to < 65 Years and = 65 Years of Age) (Per Protocol Population).	Non-inferiority of bioCSL QIV compared to bioCSL TIV-1, and to bioCSL TIV-2 was assessed separately within each age group (18 to < 65 years and = 65 years of age) through assessment of SCR differences as described for the primary endpoint.	21 days after vaccination.	No
Secondary	Immunologic Superiority of the Alternate B Strain in bioCSL QIV, as Determined by the GMT (Statistical Analysis: GMT Ratio) for This Strain, Overall and by Age Cohort (Per Protocol Population).	Immunologic superiority of the alternate B strain (ie, the influenza B strain included in the QIV but not in the TIV formulation) in bioCSL QIV was assessed separately within each age group (18 to < 65 years and = 65 years of age), and overall. The GMT ratio was calculated as bioCSL QIV GMT/bioCSL TIV GMT for the superiority analyses, which is the reverse of how it was calculated for the non-inferiority analyses.; (GMT dispersion values are based on unadjusted GMT values.)	21 days after vaccination.	No
Secondary	Immunologic Superiority of the Alternate B Strain in bioCSL QIV, as Determined by Seroconversion Rate (SCR) (Statistical Analysis: Difference in SCR) for This Strain, Overall and by Age Cohort (Per Protocol Population)	Immunologic superiority of the alternate B strain (ie, the influenza B strain included in the QIV but not in the TIV formulation) in bioCSL QIV was assessed separately within each age group (18 to < 65 years and = 65 years of age), and overall. The SCR difference was calculated as bioCSL QIV SCR minus bioCSL TIV SCR, which is the reverse of how it was calculated for the non-inferiority analyses. For the SCR comparison superiority was demonstrated if the lower limit of the two-sided 95% CI of the difference of the seroconversion rates was greater than 0 for each B strain in QIV compared with the corresponding B strain not contained in each TIV.	21 days after vaccination.	No
Secondary	Geometric Mean of HI Titers (GMTs) Prevaccination and Postvaccination.	The immunogenicity of bioCSL QIV, bioCSL TIV-1 and bioCSL TIV-2 was assessed in terms of geometric mean HI titers (GMT) prevaccination (Day 1) and postvaccination (Day 21), in age cohorts (per protocol population).	21 days after vaccination.	No
Secondary	Geometric Mean Fold Titer Change From Prevaccination to Postvaccination.	The immunogenicity of bioCSL QIV, bioCSL TIV-1 and bioCSL TIV-2 assessed in terms of Geometric Mean Fold Increase (GMFI, defined as the geometric mean of the fold increases of postvaccination antibody titer over the prevaccination antibody titer) by Age Cohort (Per Protocol Population).	21 days after vaccination.	No
Secondary	Seroprotection Rates Prevaccination and Postvaccination.	The immunogenicity of bioCSL QIV, bioCSL TIV-1 and bioCSL TIV-2 was assessed in terms of percentage of subjects with a HI titer =40 (seroprotection rates) prevaccination (Day 1) and postvaccination (Day 21), in age cohorts (per protocol population).	21 days after vaccination.	No
Secondary	Seroconversion Rates	The immunogenicity of bioCSL QIV, bioCSL TIV-1 and bio CSL TIV-2 was assessed in terms of the seroconversion rate, ie, percentage of subjects with either a prevaccination HI titer < 1:10 and a postvaccination HI titer = 1:40, or a prevaccination titer = 1:10 and a = 4-fold increase in post-vaccination titer. Data presented in age cohorts (per protocol population).	21 days after vaccination.	No
Secondary	The Frequency and Severity of Solicited Local and Systemic Adverse Events (AEs).	The overall number of subjects experiencing at least one event of a local and systemic solicited AE, and the overall number of subjects with at least one severe (grade 3) local and systemic solicited AE.	For 7 days following vaccination.	Yes
Secondary	The Frequency of Cellulitis-like Reaction and Cellulitis.	The number of subjects experiencing at least one episode of each event.	For 28 days following vaccination.	Yes
Secondary	The Frequency and Severity of Unsolicited AEs.	The overall number of subjects experiencing at least one event of an unsolicited AE, and the overall number of subjects with at least one severe (grade 3) unsolicited AE.	For 28 days following vaccination.	Yes
Secondary	The Frequency of Serious Adverse Events (SAEs) for 6 Months Following Vaccination.	The number of participants reporting Serious Adverse Events for 6 months following vaccination.	For 6 months following vaccination.	Yes